Mexiletine: An adjuvant option for refractory pain in patients with sickle cell disease and comorbid autism spectrum disorder

This publication has 14 references indexed in Scilit:

• Sensory cognitive abnormalities of pain in autism spectrum disorder: a case–control study
  Annals of General Psychiatry, 2016
• Intravenous Lidocaine as an Adjuvant for Pain Associated with Sickle Cell Disease
  Journal of Pain & Palliative Care Pharmacotherapy, 2015
• Early insights into the neurobiology of pain in sickle cell disease: A systematic review of the literature
  Pediatric Blood & Cancer, 2015
• Pharmacotherapy for neuropathic pain in adults: a systematic review and meta-analysis
  The Lancet Neurology, 2015
• Pain as a predictor of sleep problems in youth with autism spectrum disorders
  Autism, 2014
• Intravenous Lidocaine and Mexiletine in the Management of Trigeminal Autonomic Cephalalgias
  Current Pain and Headache Reports, 2010
• Mexiletine and Lidocaine Suppress the Excitability of Dorsal Horn Neurons
  Anesthesia & Analgesia, 2009
• Mexiletine Therapy for Chronic Pain: Survival Analysis Identifies Factors Predicting Clinical Success
  Journal of Pain and Symptom Management, 2008
• Daily Assessment of Pain in Adults with Sickle Cell Disease
  Annals of Internal Medicine, 2008
• The Use of Oral Mexiletine for the Treatment of Pain after Peripheral Nerve Injury
  Anesthesiology, 1992